PMID: 9434824Jan 22, 1998Paper

Acute myeloid leukemia as a second malignancy: report of 9 pediatric patients in a single institution in Argentina

Medical and Pediatric Oncology
M S FeliceF Sackmann-Muriel

Abstract

Acute myeloid leukemia (AML) is well-recognized as one of the most important second malignancies. We report the occurrence of secondary AML (sAML) in our institution. From September 1987 to August 1996 we have observed sAML in 9 patients (median age 4 years), 5 of them previously treated for hematologic malignancies (group I): acute lymphoblastic leukemia (n = 2), AML (n = 1), non-Hodgkin lymphoma (n = 1). Hodgkin disease (n = 1), and 4 of these 9 patients treated for solid tumors (group II): neuroblastoma (n = 1), retinoblastoma (n = 1), Wilms tumor (n = 1), and central nervous system germinoma (n = 1). All the patients had topoisomerase II inhibitors as part of treatment of their first malignancy, but only 5 patients received epipodophyllotoxins. Alkylating agents were part of primary therapy in 8 of 9 patients. The latency period for the development sAML was 26.5 (range = 2-55) months. The morphologic FAB features of sAML were M5 (n = 5), M4 (n = 3), and M2 (n = 1). Cytogenetic studies showed r11q23 in 3 patients, all of them with prior hematological malignancies. Initial therapy for sAML in all cases was chemotherapy (including cytarabine in combination with idarubicin and etoposide or doxorubicin or mitoxantrone). Three pa...Continue Reading

References

Jan 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S P HungerM P Link
Mar 14, 1992·Journal of the National Cancer Institute·F X Mahaney
Dec 12, 1991·The New England Journal of Medicine·C H PuiJ T Sandlund
Apr 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A T MeadowsS G Sallan
Nov 1, 1984·Cancer Genetics and Cytogenetics·D L WilliamsW Lemonds
Sep 1, 1995·Medical and Pediatric Oncology·R K MulhernE I Thompson
Apr 1, 1995·Leukemia Research·J M Bennett
Feb 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S B Murphy

❮ Previous
Next ❯

Citations

Jan 19, 2007·Journal of Pediatric Hematology/oncology·Bina Sharine MenonLin Hai Peng
Sep 7, 2007·Journal of Pediatric Hematology/oncology·Michael WeintraubJacob Pèer

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.